Calico

Also Clin1 ALS; ABBV-CLS-579 Clin1 solid tumors (partner: AbbVie); ABBV-CLS-484 Clin1 solid tumors (partner: AbbVie), undisclosed programs RD/Clin0 oncology, neurological diseases, tissue homeostasis & repair

Calico Life Sciences is investigating the basic biology of aging using state-of-the-art technology and advanced computation. Unlike traditional biotechnology companies, Calico focuses on biology first with its wide range of equipment and facilities and uses that information to develop interventions that enable people to live longer and healthier lives. For example, Calico works with different model organisms such as yeast, worms, mice and naked mole rats. The long-term aim of Calico is to identify new targets, not being pursued by others, for diseases commonly associated with aging. Calico’s portfolio currently includes more than 20 early- and late-stage preclinical compounds in cancer, neurological diseases and tissue homeostasis and repair.